anti-BCMA/anti-GPRC5D CAR T cells OriC321

{
  "id": "MLC-T-ONC-010167",
  "term": "anti-BCMA/anti-GPRC5D CAR T cells OriC321",
  "field": "Oncology and biomedicine",
  "definition": "A preparation of T lymphocytes engineered to express chimeric antigen receptor(s) (CAR) targeting the human tumor-associated antigens (TAAs) B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) and G-protein coupled receptor family C group 5 member D (GPRC5D) and fused to as of yet not fully elucidated co-stimulatory domains, with potential immunostimulating and antineoplastic activities. Upon administration, the anti-BCMA/anti-GPRC5D CAR T cells OriC321 specifically and simultaneously target and bind to tumor cells expressing BCMA and/or GPRC5D. This induces selective toxicity in tumor cells that express BCMA and/or GPRC5D. BCMA, a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF). BCMA is found on the surfaces of plasma cells, is overexpressed on malignant plasma cells and plays a key role in plasma cell proliferation and survival. GPRC5D is overexpressed in certain malignancies, such as multiple myeloma, while minimally expressed in normal, healthy cells. It plays a key role in tumor cell proliferation.",
  "synonyms": [
    "BCMA/GPRC5D dual target CAR T cells OriC321",
    "bispecific BCMA/GPRC5D-targeted CAR T cells OriC321",
    "BCMA/GPRC5D-targeted CAR T cells OriC321"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/anti-bcma-anti-gprc5d-car-t-cells-oric321/"
}